Literature DB >> 3076129

Side effects of topical corticosteroids and their prevention.

K Takeda1, S Arase, S Takahashi.   

Abstract

The goal of topical corticosteroid therapy is to maximise the clinical benefits of this highly effective group of drugs, while minimising their adverse effects. Many types of steroid-induced skin lesions and skin atrophy can occur by such mechanisms as the suppression of cell proliferation, immunosuppression, or hormonal activity, and a trend towards an increased incidence of steroid-induced dermatological disturbances has been observed in recent years. Systemic effects have also been documented. To reduce the risk of local and systemic effects, it is necessary to consider factors such as the intrinsic potency of a drug, type of vehicle used and frequency of application. A potent drug may be changed to a less potent one, or the dosage reduced. Once-daily application is often as effective as three-times-daily application, and intermittent application can also be recommended. The concept of an 'ante-drug' promises new developments in topical corticosteroid therapy. An 'ante-drug', e.g. difluprednate, has potent efficacy but fewer side effects than conventional therapy, since it acts at the application site and then is metabolised to less active or inactive compounds before reaching the systemic circulation. It is likely that future corticosteroids will have the attributes of an ante-drug, thus greatly reducing the risk of systemic effects. At present, however, it is still necessary to recognise the influence of various drug and patient factors that contribute to side effects, in order to balance clinical efficacy with an acceptable side effect profile.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3076129     DOI: 10.2165/00003495-198800365-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  7 in total

1.  TOPICAL ACTIVITIES OF BETAMETHASONE ESTERS IN MAN.

Authors:  A W MCKENZIE; R M ATKINSON
Journal:  Arch Dermatol       Date:  1964-05

2.  Steroid-induced atrophy in an animal and human model.

Authors:  J D Kirby; D D Munro
Journal:  Br J Dermatol       Date:  1976-03       Impact factor: 9.302

3.  Comparison of two application schedules for clobetasol 17 propionate.

Authors:  L C vd Harst; H de Jonge; F Pot; M K Polano
Journal:  Acta Derm Venereol       Date:  1982       Impact factor: 4.437

4.  Anti-inflammatory steroids without pituitary-adrenal suppression.

Authors:  H J Lee; M R Soliman
Journal:  Science       Date:  1982-02-19       Impact factor: 47.728

5.  Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications.

Authors:  R Woodford; J M Haigh; B W Barry
Journal:  Dermatologica       Date:  1983

6.  Treatment of psoriasis and atopic dermatitis with halcinonide cream applied once and three times daily.

Authors:  T Fredriksson; A Lassus; J Bleeker
Journal:  Br J Dermatol       Date:  1980-05       Impact factor: 9.302

7.  [Development and regression of dermal corticosteroid atrophy. 2. Changes in compression rate].

Authors:  E Hinz; D Lubach
Journal:  Derm Beruf Umwelt       Date:  1986 Nov-Dec
  7 in total
  8 in total

Review 1.  Topical corticosteroids. Which drug and when?

Authors:  B Giannotti; N Pimpinelli
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

2.  0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.

Authors:  H C Korting; D Vieluf; M Kerscher
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris.

Authors:  H C Korting; H Zienicke; M Schäfer-Korting; O Braun-Falco
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Treatment of Seborrheic Dermatitis Using a Novel Herbal-based Cream.

Authors:  Deganit Barak-Shinar; Ruben Del Río; Lawrence J Green
Journal:  J Clin Aesthet Dermatol       Date:  2017-04

Review 5.  Topical corticosteroids and unwanted local effects. Improving the benefit/risk ratio.

Authors:  M Mori; N Pimpinelli; B Giannotti
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

6.  Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study.

Authors:  Alberto de la Fuente-García; Minerva Gómez-Flores; Leonardo Mancillas-Adame; Jorge Ocampo-Candiani; Oliverio Welsh-Lozano; Jesús Zacarías Villarreal Pérez; José Gerardo González-González; Fernando Lavalle-González
Journal:  Indian Dermatol Online J       Date:  2014-04

Review 7.  Steroid Phobia: Is There a Basis? A Review of Topical Steroid Safety, Addiction and Withdrawal.

Authors:  Sean Yilong Tan; Nisha Suyien Chandran; Ellie Ci-En Choi
Journal:  Clin Drug Investig       Date:  2021-08-18       Impact factor: 2.859

8.  Rational and ethical use of topical corticosteroids based on safety and efficacy.

Authors:  Sanjay K Rathi; Paschal D'Souza
Journal:  Indian J Dermatol       Date:  2012-07       Impact factor: 1.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.